Signifor (Pasireotide Diaspartate) Patent Expiration, LOE Window & CMS Spending

Signifor (Pasireotide Diaspartate) by Recordati Rare Diseases: FDA Orange Book core substance LOE 2026-12-14, 0 AB generics, $2.4M 2024 CMS Part D & Medicaid spend, and 27 CA HCAI SB 17 wholesale price filings.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorRecordati Rare Diseases
FDA Application & PathwayN200677 (NDA)
Exclusivity / Cliff HorizonImmediate Cliff (2025-2027)
Core Active-Ingredient LOE Date2026-12-14
Last Listed Patent or Exclusivity Date2026-12-14
Orange Book Patents (*PED Extensions)1 patents (0 *PED)
Active AB-Rated Generic Competitors0
2024 CMS Total Public Spend$2.4M
2024 Medicare Part D Spend$2.1M
2024 Medicaid Spend$335K
Reported Wholesale Price Change (CA SB 17)27 WAC filings (max 37.8% 2-yr change)